Quarterly report pursuant to Section 13 or 15(d)

Significant Accounting Policies - Restatement adjustments (Details)

v3.20.1
Significant Accounting Policies - Restatement adjustments (Details) - USD ($)
 3 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Sep. 30, 2019
Sep. 30, 2018
Statement of Operations        
General and administrative expenses $ 2,554,680 $ 422,010    
Research and development expenses 1,227,686 4,876    
Research and development expense- licenses acquired 0 1,046,965    
Total operating expenses 3,782,366 1,473,851    
Loss from operations (3,782,366) (1,473,851)    
Interest expense (1,311) (14,637)    
Total other expenses   (14,637)    
Net loss $ (4,505,550) $ (1,488,488)    
Basic and diluted loss per common share $ (0.26) $ (0.25)    
Weighted average shares outstanding 17,071,678 5,863,333    
Assets        
Intangible assets, net $ 20,833   $ 145,833  
Total assets 9,877,463 $ 137,190 12,531,397  
Liabilities        
Accounts payable and accrued expenses   165,169    
Warrant liabilities   104,902    
Convertible notes payable, net   259,614    
Total liabilities 2,849,403 529,685 2,502,013  
Stockholders' equity (deficit)        
Additional paid-in capital 38,532,101 1,137,512 37,027,875  
Accumulated deficit (31,505,749) (1,530,440) (27,000,199)  
Total stockholders' equity (deficit) 7,028,060 (392,495) 10,029,384 $ (41,896)
Total liabilities and stockholders' equity (deficit) 9,877,463 137,190 $ 12,531,397  
Condensed Consolidated Statements of Cash Flows        
Net loss (4,505,550) (1,488,488)    
Adjustments to reconcile net loss to net cash used by operating activities        
Stock-based compensation 1,504,226 293,303    
Research and development expense - license acquired 0 1,046,965    
Non-cash amortization on convertible notes 0 9,614    
Non-cash interest expense on convertible notes 0 5,023    
Changes in operating assets and liabilities        
Accounts payable and accrued expenses   118,649    
Other current assets   1    
Net Cash used in Operating Activities (2,441,486) (14,933)    
Cash flows from investing activities        
Payment of transaction costs for license acquired 0 (43,463)    
Cash paid for license acquired 0 (54,000)    
Net cash used in investing activities (68,400) (97,463)    
Cash flows from financing activities        
Repurchase of common stock 0 (14)    
Net cash used in financing activities (73,426) (14)    
Net decrease in cash and cash equivalents (2,583,312) (112,410)    
Cash and cash equivalents, beginning of period   249,600    
Cash and cash equivalents, end of period   137,190    
Non-cash investing and financing activities:        
Common stock for research and development expense-license acquired 0 844,600    
Fair value of warrant liability issued for research and development expense- license acquired $ 0 104,902    
As Previously Reported        
Statement of Operations        
General and administrative expenses   620,692    
Research and development expenses   54,459    
Total operating expenses   675,151    
Loss from operations   (675,151)    
Interest expense   (4,521)    
Total other expenses   (4,521)    
Net loss   $ (679,672)    
Basic and diluted loss per common share   $ (0.13)    
Weighted average shares outstanding   5,315,870    
Assets        
Intangible assets, net   $ 1,488,301    
Total assets   1,625,491    
Liabilities        
Accounts payable and accrued expenses   164,667    
Warrant liabilities   163,356    
Convertible notes payable, net   250,000    
Total liabilities   578,023    
Stockholders' equity (deficit)        
Additional paid-in capital   1,768,659    
Accumulated deficit   (721,624)    
Total stockholders' equity (deficit)   1,047,468    
Total liabilities and stockholders' equity (deficit)   1,625,491    
Condensed Consolidated Statements of Cash Flows        
Net loss   (679,672)    
Adjustments to reconcile net loss to net cash used by operating activities        
Stock-based compensation   444,105    
Changes in operating assets and liabilities        
Accounts payable and accrued expenses   123,170    
Net Cash used in Operating Activities   (112,397)    
Cash flows from financing activities        
Repurchase of common stock   (14)    
Proceeds from stock subscription   1    
Net cash used in financing activities   (13)    
Net decrease in cash and cash equivalents   (112,410)    
Cash and cash equivalents, beginning of period   249,600    
Cash and cash equivalents, end of period   137,190    
Non-cash investing and financing activities:        
Common stock for research and development expense-license acquired   1,324,945    
Fair value of warrant liability issued for research and development expense- license acquired   163,356    
Restatement Adjustment        
Statement of Operations        
General and administrative expenses   (198,682)    
Research and development expenses   (49,583)    
Research and development expense- licenses acquired   1,046,965    
Total operating expenses   798,700    
Loss from operations   (798,700)    
Interest expense   (10,116)    
Total other expenses   (10,116)    
Net loss   (808,816)    
Assets        
Intangible assets, net   (1,488,301)    
Total assets   (1,488,301)    
Liabilities        
Accounts payable and accrued expenses   502    
Warrant liabilities   (58,454)    
Convertible notes payable, net   9,614    
Total liabilities   (48,338)    
Stockholders' equity (deficit)        
Additional paid-in capital   (631,147)    
Accumulated deficit   (808,816)    
Total stockholders' equity (deficit)   (1,439,963)    
Total liabilities and stockholders' equity (deficit)   (1,488,301)    
Condensed Consolidated Statements of Cash Flows        
Net loss   (808,816)    
Adjustments to reconcile net loss to net cash used by operating activities        
Stock-based compensation   (150,802)    
Research and development expense - license acquired   1,046,965    
Non-cash amortization on convertible notes   9,614    
Non-cash interest expense on convertible notes   5,023    
Changes in operating assets and liabilities        
Accounts payable and accrued expenses   (4,521)    
Other current assets   1    
Net Cash used in Operating Activities   97,464    
Cash flows from investing activities        
Payment of transaction costs for license acquired   (43,463)    
Cash paid for license acquired   (54,000)    
Net cash used in investing activities   (97,463)    
Cash flows from financing activities        
Proceeds from stock subscription   (1)    
Net cash used in financing activities   (1)    
Non-cash investing and financing activities:        
Common stock for research and development expense-license acquired   (480,345)    
Fair value of warrant liability issued for research and development expense- license acquired   $ (58,454)